Sunday, December 06, 2020 1:05:19 PM
So, dilution is a good thing, then?
Yeah, sure. Over 1B shares already added to the O/S, and 15B more through the warrants. Funny thing about those warrants, there’s a cashless exercise formula in them, which means they don’t have to give the company a plug nickel in cash to exercise them, just have to sacrifice some according to what the PPS is at the time of exercise.
And this company is still in debt. Auctus has $3.3M of a new convertible note (plus warrants) for their old note, plus $3.5M for their DIP and operational financing, so the overall debt was reduced by just over half.
And they still don’t have funding for their phase 2 trial.
Yeah, sure. Over 1B shares already added to the O/S, and 15B more through the warrants. Funny thing about those warrants, there’s a cashless exercise formula in them, which means they don’t have to give the company a plug nickel in cash to exercise them, just have to sacrifice some according to what the PPS is at the time of exercise.
And this company is still in debt. Auctus has $3.3M of a new convertible note (plus warrants) for their old note, plus $3.5M for their DIP and operational financing, so the overall debt was reduced by just over half.
And they still don’t have funding for their phase 2 trial.
I swear I’ll never use the phrase “you can’t make this stuff up” ever again after being on the OTC. Apparently you can.
Recent BRTX News
- BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform • GlobeNewswire Inc. • 04/21/2026 12:00:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/20/2026 09:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/13/2026 09:22:23 PM
- BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform • GlobeNewswire Inc. • 04/07/2026 12:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/03/2026 06:46:20 PM
- BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 08:20:29 PM
- BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 • GlobeNewswire Inc. • 03/05/2026 01:00:00 PM
- BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy • GlobeNewswire Inc. • 03/04/2026 01:00:00 PM
- BioRestorative secures Australian patent protection for ThermoStem® obesity therapy platform • IH Market News • 02/24/2026 03:14:07 PM
- BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs • GlobeNewswire Inc. • 02/24/2026 01:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/23/2026 09:50:39 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 09:12:24 PM
- BioRestorative Announces Closing of $5.0 Million Public Offering • GlobeNewswire Inc. • 02/14/2026 01:30:00 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/13/2026 02:48:15 PM
- BioRestorative Announces Pricing of $5.0 Million Public Offering • GlobeNewswire Inc. • 02/12/2026 03:30:00 AM
- BioRestorative Announces Positive Outcome from Type B Meeting with FDA • GlobeNewswire Inc. • 02/11/2026 12:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/10/2026 10:20:59 PM
- BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 02/10/2026 01:00:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/09/2026 10:31:45 PM
